Skip to main content
logo
Lyell Immunopharma logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
8.19
+0.20 (2.50%)
Oct 15, 2026, 4:00 PM EDT - Market closed

Lyell Immunopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-248.48-274.45-342.99-234.63-183.12-250.22
Depreciation & Amortization
9.5211.5419.6320.2518.0213.62
Loss (Gain) From Sale of Assets
-0.33.341.341.510.11.21
Asset Writedown & Restructuring Costs
66.3367.78138.48---
Loss (Gain) From Sale of Investments
15.4114.26-1.713.331.1538.35
Stock-Based Compensation
39.6341.8333.1447.0881.9262.2
Other Operating Activities
-21.21-4.43-7.17-4.65-5.624.57
Change in Accounts Payable
0.47-2.34-3.231.460.670.09
Change in Unearned Revenue
-----84.65-10.51
Change in Other Net Operating Assets
5.38-7.560.111.961.9714.43
Operating Cash Flow
-133.26-150.02-162.39-163.69-169.56-126.25
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.71-0.78-0.46-2.69-24.28-65.5
Sale of Property, Plant & Equipment
0.290.29----
Cash Acquisitions
-41.2-41.2-31.35---
Investment in Securities
46.5995.79154.23186.7312.74-56.07
Investing Cash Flow
4.9854.1122.42184.05-11.54-121.57

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
102.4750.411.42.211.1401.24
Repurchase of Common Stock
-0-0-0.08-0.46-0.46-
Financing Cash Flow
102.4750.411.331.7410.64401.24

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-25.82-45.52-38.6422.1-170.46153.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-133.97-150.8-162.86-166.38-193.83-191.75
Free Cash Flow Growth
------
Free Cash Flow Margin
-496188.89%-418900.00%-266980.33%-127984.62%-228.89%-1800.50%
Free Cash Flow Per Share
-6.37-8.82-12.46-13.26-15.69-28.22
Levered Free Cash Flow
-72.81-81.47-67.56-90.36-53.9-129.82
Unlevered Free Cash Flow
-72.81-81.47-67.56-90.36-53.9-129.82

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
5.84-9.89-3.123.42-82.024.01
SEC Filings: 10-K · 10-Q